David Shulman, MD
Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Image
David Shulman, MD
Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Medical Services
Education
Medical School
Harvard Medical School
2013
Boston
MA
Residency
Pediatrics
Boston Combined Residency Program (BCRP)
Boston
MA
Fellowship
Boston Children's Hospital/Dana-Farber Cancer Institute
Boston
MA
Professional History
Dr. David Shulman studies novel therapies and biomarkers for advanced pediatric solid tumors within the Dana-Farber Experimental Therapeutics Program. In addition to early phase clinical trials, Dr. Shulman also studies circulating tumor DNA as a potential tool to improve the ways in which we treat patients with bone tumors,
Publications
Emerging Role of Blood-based Biomarkers in Sarcomas. View Abstract
Case 14-2025: A 29-Year-Old Woman with Peritonsillar Swelling and Bleeding. View Abstract
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. View Abstract
Targeted-Agent Continual Reassessment Method: A Novel Bayesian Enrichment Design for Phase I Trials of Molecularly Targeted Therapies. View Abstract
Statistical Fragility of Findings From Randomized Phase 3 Trials in Pediatric Oncology. View Abstract
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report. View Abstract
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. View Abstract
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. View Abstract
Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. View Abstract
Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. View Abstract
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. View Abstract
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. View Abstract
Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. View Abstract
Derivation and validation of a risk classification tree for patients with synovial sarcoma. View Abstract
Rapid and highly sensitive approach for multiplexed somatic fusion detection. View Abstract
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. View Abstract
Facial Paralysis From Post-transplant Lymphoproliferative Disorder. View Abstract
Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. View Abstract
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. View Abstract
Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. View Abstract
Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. View Abstract
Landscape of phase 1 clinical trials for minors with cancer in the United States. View Abstract
Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. View Abstract
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. View Abstract
Sponsorship of oncology clinical trials in the United States according to age of eligibility. View Abstract
DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. View Abstract
The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. View Abstract
Using Liquid Biopsy in the Treatment of Patient with OS. View Abstract
Second malignancies in patients treated for Ewing sarcoma: A systematic review. View Abstract
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Timing of first-in-child trials of FDA-approved oncology drugs. View Abstract
Winning the RACE: Expanding pediatric cancer drug approvals. View Abstract
Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. View Abstract
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. View Abstract
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. View Abstract
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. View Abstract
Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. View Abstract
Implementation and Validation of Telepathology Triage at Cancer Referral Center in Rural Rwanda. View Abstract
Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. View Abstract
Diagnosis of cancer in rural Rwanda: early outcomes of a phased approach to implement anatomic pathology services in resource-limited settings. View Abstract
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. View Abstract
Congenital hyperreninemic hypoaldosteronism unlinked to the aldosterone synthase (CYP11B2) gene. View Abstract
Fentanyl anesthesia in familial dysautonomia. View Abstract